The arrival of Wegovy, a {semaglutide-based|GLP-1 receptor drug, in the British Isles has prompted thorough review and the creation of defined guidelines for its use. Current national stance emphasizes that Wegovy is primarily intended for individuals with obesity, or those with linked health conditions such as type 2 diabetes and cardiovascular di